Case 21.4
If initial screening studies (laboratory, endoscopic and/or radiographic studies) to rule out other causes of presenting symptoms raise concern for VEO-IBD, which additional second-tier testing should be considered (Select all that apply)
Immunoglobulins
Lymphocyte subsets
Neutrophil oxidative burst assay
TB testing
TB Testing is necessary before starting biologic therapy for IBD
Vaccine titers
Hep B testing is necessary before starting biologic therapy for IBD
Collaboration with immunology is an important consideration in VEO IBD care. The identification of several monogenic defects has led to effective targeted therapies
| GROUP | Age range (years) |
| Pediatric onset IBD | Younger than 17 |
| Early onset IBD | Younger than 10 |
| Very early onset IBD | Younger than 6 |
| Infantile | Younger than 2 |
| Neonatal | First 28 days of life |
Early Onset IBD | Adult IBD |
Colon involved: 80 % in less than 10 years of age | Colon only involved < 20 % |
Ileum involved rare at < 10 years | Ileum involved up to 80 % |
Positive family history 40-50 % | Positive Family History 14-20 % |